Abstract Background Diabetes continues to pose a major challenge to the global health arena, while existing diagnostic and therapeutic toolkit are limited by invasive delivery methods, delayed glucose control, patient non-compliance, and long-term economic costs. These impediments have accelerated interest in nanotechnology-based methodologies to tackle diabetes. Main body of the abstract Recent advanced nano-systems have enabled the development of minimally invasive nanoscale glucose sensors and nanoparticle-derived imaging tools that facilitate continuous monitoring and early disease identification. In parallel, glucose-sensitive nanomaterials have been engineered to more closely replicate physiological insulin secretion. Nanocarrier platforms are also being explored for non-invasive insulin delivery, targeted gene silencing, and immunoprotective cell-based therapies aimed at preserving or restoring pancreatic β-cell function. Collectively, these approaches enhance sensitivity and targeting precision while advancing the prospect of closed-loop glycemic control. Despite this encouraging progression, a number of critical challenges persist. Concerns surrounding long-term biocompatibility and potential toxicity, inflammatory reactions to implantable systems, sensor instability, limitations in scalable manufacturing, and complex regulatory pathways continue to impede clinical translation. Moreover, a substantial proportion of nanotechnology-integrated solutions remain confined to preclinical research or early-stage clinical evaluation. Short conclusion While nanotechnology offers a compelling vision for the future of diabetes care, its translation into clinical practice demands thorough safety assessment, standardized frameworks, and evidence from large-scale clinical studies. Graphical abstract
Sarkhel et al. (2026) studied this question.